KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

• Published in: Future oncology (London, England) Vol. 15; no. 10; pp. 1057 - 1066
• Main Authors: Kato, Ken, Shah, Manish A, Enzinger, Peter, Bennouna, Jaafar, Shen, Lin, Adenis, Antoine, Sun, Jong-Mu, Cho, Byoung Chul, Özgüro lu, Mustafa, Kojima, Takashi, Kostorov, Vladimir, Hierro, Cinta, Zhu, Ying, McLean, Lee Anne, Shah, Sukrut, Doi, Toshihiko
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.04.2019; Future Medicine
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies Monoclonal, Humanized / administration & dosage; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Cancer; Cancer therapies; Carcinoma, Squamous Cell / drug therapy; Carcinoma, Squamous Cell / secondary; Chemotherapy; Double-Blind Method; Esophageal cancer; Esophageal Neoplasms / drug therapy; Esophageal Neoplasms / pathology; esophagogastric junction cancer; Female; Fluorouracil / administration & dosage; Follow-Up Studies; gastrointestinal/esophageal; Gene expression; Health risk assessment; Human health and pathology; Humans; Hépatology and Gastroenterology; Immunotherapy; Life Sciences; Male; Metastasis; Middle Aged; Monoclonal antibodies; PD-1; PD-L1; pembrolizumab; Prognosis; Research Design; Response rates; Squamous cell carcinoma; squamous cell carcinoma of the esophagus; Studies; Survival Rate; Targeted cancer therapy; Tumors; Young Adult; United States > US; pembrolizumab; esophageal cancer; gastrointestinal/esophageal; squamous cell carcinoma of the esophagus; immunotherapy; PD-L1; esophagogastric junction cancer; PD-1; chemotherapy; Esophagogastric junction cancer; Squamous cell carcinoma of the esophagus; Gastrointestinal/esophageal; Chemotherapy; Pembrolizumab; Immunotherapy; Esophageal cancer
• ISSN: 1479-6694; 1744-8301; 1744-8301
• DOI: 10.2217/fon-2018-0609

Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. : NCT03189719.